A ceremony is set for Thursday to mark the completion of a new laboratory building at Roche Diagnostics Corp.'s major Indianapolis campus expansion. Officials say the facility is the “first significant” project to be finished as part of the $300 million effort. September 24, 2014
INDIANAPOLIS, Ind. – Mayor Greg Ballard, city and state leaders will join Roche Diagnostics executives, including President and CEO Jack Phillips and Senior Vice President and Head of Roche Diagnostics Operations Tom Adkins, for a ribbon-cutting ceremony on the company's northeast side campus Thursday, Sept. 25, to celebrate the opening of its new laboratory building. This marks the first significant construction project to be completed as part of a $300 million, multi-year campus transformation, which was first announced by Roche and former Governor Mitch Daniels in 2012.
WHO: Mayor Greg Ballard; Sen. Jim Merritt; Rep. Christina Hale; City/County Councilors Mike McQuillen, Marilyn Pfisterer and Virginia Cain
Jack Phillips, President and CEO, Roche Diagnostics Corporation
Tom Adkins, SVP and Head of Roche Diagnostics Operations
WHEN: Thursday, Sept. 25, 9-9:30 a.m.
WHERE: Roche Diagnostics campus, Indianapolis
The Roche Diagnostics North American headquarters is home to U.S. research and development, laboratory, manufacturing, distribution, information technology and corporate headquarters operations in support of its diagnostics business areas: diabetes care, centralized diagnostics, molecular diagnostics, tissue diagnostics and point of care. About 4,600 employees report into Indianapolis, with about 3,000 working on-site.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Source: Roche Diagnostics Corp.